Non-Pulmonary Mechanisms of Action of Ambroxol in In Vivo Experimental Models: a Systematic Review

IF 2.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Fundamental & Clinical Pharmacology Pub Date : 2026-03-13 DOI:10.1111/fcp.70077

Michelline Joana Tenório Albuquerque Madruga Mesquita, Anne Caroline Silva Nogueira da Cruz, Rafael de Abreu Lima, Joana Tenório-Meireles, Arney José Nogueira Farias, Isabela Nogueira Santos, Gustavo Frota, Taciana Gabrielle Pinheiro de Moura Carvalho, Rafael Antônio Freire Carvalho, Jorge Antônio Meireles-Teixeira, Tereza Prazeres, Rafael Cardoso Carvalho, Maria do Socorro de Sousa Cartágenes, João Batista Santos Garcia

{"title":"Non-Pulmonary Mechanisms of Action of Ambroxol in In Vivo Experimental Models: a Systematic Review","authors":"Michelline Joana Tenório Albuquerque Madruga Mesquita, Anne Caroline Silva Nogueira da Cruz, Rafael de Abreu Lima, Joana Tenório-Meireles, Arney José Nogueira Farias, Isabela Nogueira Santos, Gustavo Frota, Taciana Gabrielle Pinheiro de Moura Carvalho, Rafael Antônio Freire Carvalho, Jorge Antônio Meireles-Teixeira, Tereza Prazeres, Rafael Cardoso Carvalho, Maria do Socorro de Sousa Cartágenes, João Batista Santos Garcia","doi":"10.1111/fcp.70077","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Repositioning offers a cost-effective approach to discovering new therapeutic applications for existing medications. Ambroxol, primarily used as a mucolytic for respiratory diseases, has demonstrated anti-inflammatory, analgesic, and antioxidant properties, suggesting potential benefits in non-pulmonary conditions. This study conducted a systematic review to evaluate the efficacy of ambroxol in experimental disease models unrelated to the respiratory system.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Following registration in the Open Science Framework and adherence to the PICO strategy for formulating the guiding question, searches were performed in PUBMED/MEDLINE, EMBASE, and SCOPUS using the keywords: (Ambroxol) AND (Anti-Inflammatory Agents OR Analgesics OR Antioxidants) AND (Animals OR in vivo). The SYRCLE tool assessed methodological quality. Among 353 identified records, eight articles met eligibility criteria.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>These studies investigated ambroxol's effects in models of gastric lesions, neuropathic pain, psoriasis-like skin inflammation, hemorrhagic cystitis, and ischemia/reperfusion injuries in the liver and kidneys. Ambroxol doses ranged from 5 to 1000 mg/kg, predominantly administered orally. Its antioxidant properties were demonstrated by reducing free radicals and increasing enzymatic activity (SOD, CAT, GSH). Anti-inflammatory effects included a decrease in pro-inflammatory cytokines (TNF-α, IL-1β) and histological improvements. Antinociceptive action was observed through inhibition of voltage-gated sodium channels and reduction of oxidative stress, alleviating neuropathic pain.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Despite ambroxol's widespread clinical use, limited research has explored its non-respiratory applications. Existing studies suggest its promising therapeutic potential, reinforcing the need for further investigation into its role as an alternative treatment for various inflammatory and oxidative stress–related conditions beyond pulmonary diseases.</p>\n </section>\n </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"40 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12987714/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/fcp.70077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Repositioning offers a cost-effective approach to discovering new therapeutic applications for existing medications. Ambroxol, primarily used as a mucolytic for respiratory diseases, has demonstrated anti-inflammatory, analgesic, and antioxidant properties, suggesting potential benefits in non-pulmonary conditions. This study conducted a systematic review to evaluate the efficacy of ambroxol in experimental disease models unrelated to the respiratory system.

Methods

Following registration in the Open Science Framework and adherence to the PICO strategy for formulating the guiding question, searches were performed in PUBMED/MEDLINE, EMBASE, and SCOPUS using the keywords: (Ambroxol) AND (Anti-Inflammatory Agents OR Analgesics OR Antioxidants) AND (Animals OR in vivo). The SYRCLE tool assessed methodological quality. Among 353 identified records, eight articles met eligibility criteria.

Results

These studies investigated ambroxol's effects in models of gastric lesions, neuropathic pain, psoriasis-like skin inflammation, hemorrhagic cystitis, and ischemia/reperfusion injuries in the liver and kidneys. Ambroxol doses ranged from 5 to 1000 mg/kg, predominantly administered orally. Its antioxidant properties were demonstrated by reducing free radicals and increasing enzymatic activity (SOD, CAT, GSH). Anti-inflammatory effects included a decrease in pro-inflammatory cytokines (TNF-α, IL-1β) and histological improvements. Antinociceptive action was observed through inhibition of voltage-gated sodium channels and reduction of oxidative stress, alleviating neuropathic pain.

Conclusions

Despite ambroxol's widespread clinical use, limited research has explored its non-respiratory applications. Existing studies suggest its promising therapeutic potential, reinforcing the need for further investigation into its role as an alternative treatment for various inflammatory and oxidative stress–related conditions beyond pulmonary diseases.

Abstract Image

查看原文本刊更多论文

氨溴索在体内实验模型中的非肺作用机制：系统综述。

背景：重新定位为发现现有药物的新治疗应用提供了一种经济有效的方法。氨溴索主要用作呼吸系统疾病的黏液解药，具有抗炎、镇痛和抗氧化的特性，这表明它对非肺部疾病有潜在的益处。本研究对氨溴索在与呼吸系统无关的实验性疾病模型中的疗效进行了系统评价。方法：在开放科学框架注册并遵循制定指导问题的PICO策略后，在PUBMED/MEDLINE， EMBASE和SCOPUS中使用关键词（氨溴索）和（抗炎药或镇痛药或抗氧化剂）和（动物或体内）进行检索。sycle工具评估方法学质量。在353条确定的记录中，有8篇文章符合资格标准。结果：这些研究探讨了氨溴索在胃病变、神经性疼痛、牛皮癣样皮肤炎症、出血性膀胱炎和肝脏和肾脏缺血/再灌注损伤模型中的作用。氨溴索的剂量为5至1000毫克/公斤，主要是口服。其抗氧化性能通过降低自由基和提高酶活性（SOD、CAT、GSH）来证明。抗炎作用包括降低促炎细胞因子（TNF-α, IL-1β）和组织学改善。通过抑制电压门控钠通道和减少氧化应激，减轻神经性疼痛，观察到抗痛觉作用。结论：尽管氨溴索临床应用广泛，但对其非呼吸系统应用的研究有限。现有研究表明其具有良好的治疗潜力，因此需要进一步研究其作为肺部疾病以外各种炎症和氧化应激相关疾病的替代治疗方法的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fundamental & Clinical Pharmacology 医学-药学

CiteScore

5.30

自引率

6.90%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including: Antimicrobial, Antiviral Agents Autonomic Pharmacology Cardiovascular Pharmacology Cellular Pharmacology Clinical Trials Endocrinopharmacology Gene Therapy Inflammation, Immunopharmacology Lipids, Atherosclerosis Liver and G-I Tract Pharmacology Metabolism, Pharmacokinetics Neuropharmacology Neuropsychopharmacology Oncopharmacology Pediatric Pharmacology Development Pharmacoeconomics Pharmacoepidemiology Pharmacogenetics, Pharmacogenomics Pharmacovigilance Pulmonary Pharmacology Receptors, Signal Transduction Renal Pharmacology Thrombosis and Hemostasis Toxicopharmacology Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.